PWE-053 Outcomes of anti-tnf versus vedolizumab therapy for ulcerative colitis: the leeds experience

MLA

Johnston, Aj, et al. “PWE-053 Outcomes of Anti-Tnf versus Vedolizumab Therapy for Ulcerative Colitis: The Leeds Experience.” Gut, vol. 66, no. Supplement 2, Jan. 2017, p. A152. EBSCOhost, https://doi.org/10.1136/gutjnl-2017-314472.298.

APA

Johnston, A., Lenti, M., O, C. A., Selinger, C., Ford, A., & Hamlin, P. (2017). PWE-053 Outcomes of anti-tnf versus vedolizumab therapy for ulcerative colitis: the leeds experience. Gut, 66(Supplement 2), A152. https://doi.org/10.1136/gutjnl-2017-314472.298

Chicago

Johnston, Aj, M Lenti, Connor, A O, C Selinger, Ac Ford, and Pj Hamlin. 2017. “PWE-053 Outcomes of Anti-Tnf versus Vedolizumab Therapy for Ulcerative Colitis: The Leeds Experience.” Gut 66 (Supplement 2): A152. doi:10.1136/gutjnl-2017-314472.298.